Courtney D DiNardo

Courtney D DiNardo

UNVERIFIED PROFILE

Are you Courtney D DiNardo?   Register this Author

Register author
Courtney D DiNardo

Courtney D DiNardo

Publications by authors named "Courtney D DiNardo"

Are you Courtney D DiNardo?   Register this Author

99Publications

3605Reads

22Profile Views

Myeloid malignancies with somatic mutations can be associated with an immunodeficiency phenotype.

Leuk Lymphoma 2019 Aug 16;60(8):2025-2033. Epub 2019 Jan 16.

a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1551535DOI Listing
August 2019

Severe therapy-related toxicities after treatment for Hodgkin lymphoma due to a pathogenic TERT variant and shortened telomeres.

Pediatr Blood Cancer 2019 Aug 2;66(8):e27779. Epub 2019 May 2.

Department of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27779DOI Listing
August 2019

Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation.

Am J Hematol 2019 Aug 10. Epub 2019 Aug 10.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25610DOI Listing
August 2019

Clinical applicability of proposed algorithm for identifying individuals at risk for hereditary hematologic malignancies.

Leuk Lymphoma 2019 Jul 5:1-8. Epub 2019 Jul 5.

h Department of Leukemia , The University of Texas M.D. Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1630618DOI Listing
July 2019

Hereditary myeloid malignancies.

Best Pract Res Clin Haematol 2019 06 3;32(2):163-176. Epub 2019 May 3.

Department of Leukemia, The University of Texas at MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2019.05.001DOI Listing
June 2019

Advances in patient care through increasingly individualized therapy.

Nat Rev Clin Oncol 2019 02;16(2):73-74

Division of Hematology-Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0156-2DOI Listing
February 2019

Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia.

JCO Precis Oncol 2019 6;3. Epub 2019 Feb 6.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.18.00198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448807PMC
February 2019

SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.

Clin Lymphoma Myeloma Leuk 2018 12 21;18(12):769-772. Epub 2018 Oct 21.

Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650183142
Publisher Site
http://dx.doi.org/10.1016/j.clml.2018.10.007DOI Listing
December 2018

Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.

N Engl J Med 2018 09;379(12):1186

University of Texas M.D. Anderson Cancer Center, Houston, TX

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1809507DOI Listing
September 2018

The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia.

Ther Adv Hematol 2018 Jul 1;9(7):163-173. Epub 2018 Jun 1.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620718777467DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041864PMC
July 2018

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.

J Clin Oncol 2018 06 27;36(18):1788-1797. Epub 2018 Apr 27.

Kiyomi Morita, Hagop M. Kantarjian, Feng Wang, Yuanqing Yan, Carlos Bueso-Ramos, Koji Sasaki, Ghayas C. Issa, Sa Wang, Jeffrey Jorgensen, Xingzhi Song, Jianhua Zhang, Samantha Tippen, Rebecca Thornton, Marcus Coyle, Latasha Little, Curtis Gumbs, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Michael Andreeff, Farhad Ravandi, Jorge E. Cortes, Tapan Kadia, Elias Jabbour, Guillermo Garcia-Manero, Keyur P. Patel, P. Andrew Futreal, and Koichi Takahash, The University of Texas MD Anderson Cancer Center, Houston, TX; Kiyomi Morita, The University of Tokyo, Tokyo; and Koichi Takahashi, Kyoto University, Kyoto, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6757DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008108PMC
June 2018

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

N Engl J Med 2018 Jun 2;378(25):2386-2398. Epub 2018 Jun 2.

From the University of Texas M.D. Anderson Cancer Center, Houston (C.D.D., H.M.K.); Memorial Sloan Kettering Cancer Center (E.M.S., M.S.T.) and Weill Cornell Medical College (G.J.R.), New York; Institut Gustave Roussy, Villejuif (S.B., C.W.), and Centre Hospitalier Universitaire Bordeaux, Bordeaux (A.P.) - both in France; Northwestern University, Chicago (J.K.A.); Ohio State University Wexner Medical Center, Columbus (A.S.M.); Sylvester Comprehensive Cancer Center, University of Miami, Miami (R.S.); University of Texas Southwestern Medical Center, Dallas (R.H.C.); University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco (G.N.M.), and City of Hope Medical Center, Duarte (A.S.S.) - both in California; University of Colorado School of Medicine, Aurora (D.A.P.); Sarah Cannon Research Institute, Nashville (W.D.); Massachusetts General Hospital Cancer Center (A.T.F.) and Dana-Farber Cancer Institute (R.M.S.), Boston, and Agios Pharmaceuticals, Cambridge (S.C., H.W., V.Z., K.E.Y., S.M.K., H.Y., D.D., B.F., M.G., H.L., S.A., B.W., E.C.A.) - all in Massachusetts; University of Alabama at Birmingham, Birmingham (H.P.E.); Johns Hopkins University, Baltimore (G.T.P.); Washington University School of Medicine, St. Louis (G.L.U.); Mayo Clinic, Jacksonville, FL (J.M.F.); Oregon Health and Science University Knight Cancer Institute, Portland (E.T.); Hollings Cancer Center, Medical University of South Carolina, Charleston (R.K.S.); Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Mayo Clinic, Phoenix, AZ (J.L.S.); and Cleveland Clinic, Cleveland (M.A.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1716984DOI Listing
June 2018

Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations.

Cancers (Basel) 2018 Jun 6;10(6). Epub 2018 Jun 6.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers10060187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025071PMC
June 2018

The role of IDH mutations in acute myeloid leukemia.

Future Oncol 2018 Apr 15;14(10):979-993. Epub 2018 Mar 15.

Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0523DOI Listing
April 2018

Novel Therapeutics in Acute Myeloid Leukemia.

Am Soc Clin Oncol Educ Book 2017 ;37:495-503

From the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Stanford University School of Medicine, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_175401DOI Listing
December 2017

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.

Curr Hematol Malig Rep 2017 12;12(6):537-546

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard Unit 428, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-017-0418-6DOI Listing
December 2017

Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.

Clin Ther 2017 Feb 1;39(2):359-367. Epub 2017 Feb 1.

AbbVie Inc, North Chicago, Illinois; Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2017.01.003DOI Listing
February 2017

Mutations in AML: prognostic and therapeutic implications.

Hematology Am Soc Hematol Educ Program 2016 Dec;2016(1):348-355

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2016.1.348DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142505PMC
December 2016

Time to revise the revised-International Prognostic Scoring System?

Leuk Lymphoma 2015 18;56(12):3248-9. Epub 2015 Jun 18.

a Department of Leukemia , the University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1055486DOI Listing
August 2016

Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.

Clin Lymphoma Myeloma Leuk 2016 08 5;16(8):460-5. Epub 2016 May 5.

Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650163004
Publisher Site
http://dx.doi.org/10.1016/j.clml.2016.04.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4983480PMC
August 2016

Hereditary Predispositions to Myelodysplastic Syndrome.

Int J Mol Sci 2016 May 30;17(6). Epub 2016 May 30.

Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms17060838DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926372PMC
May 2016

Targeting isocitrate dehydrogenase (IDH) in cancer.

Discov Med 2016 05;21(117):373-80

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://tatcongress.org/wp-content/uploads/2015/03/O11.3-Step
Web Search
May 2016

Great expectations in acute myeloid leukemia.

Future Oncol 2016 Feb 15;12(3):289-92. Epub 2016 Jan 15.

Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.15.308DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549654PMC
February 2016

Getting a handle on hereditary CEBPA mutations.

Blood 2015 Sep;126(10):1156-8

UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-07-657908DOI Listing
September 2015

RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype.

Br J Haematol 2015 May 22;169(3):344-51. Epub 2015 Jan 22.

Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762375PMC
May 2015

Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation.

Clin Lymphoma Myeloma Leuk 2015 Jan 21;15(1):47-51. Epub 2014 Jun 21.

Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2014.06.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849878PMC
January 2015

New treatment for acute myelogenous leukemia.

Expert Opin Pharmacother 2015 Jan 5;16(1):95-106. Epub 2014 Dec 5.

UT MD Anderson Cancer Center, Department of Leukemia , 1515 Holcombe Blvd Unit 0428 Houston, TX , USA +1 713 794 1141 ; +1 713 745 4612 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2015.981527DOI Listing
January 2015

Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia.

Expert Opin Investig Drugs 2014 Feb 9;23(2):265-72. Epub 2013 Dec 9.

University of Texas MD Anderson Cancer Center, Department of Leukemia , 1515 Holcombe Blvd, Unit 0428, Houston, TX 77030 , USA +1 713 794 5783 ; +1 713 745 4612 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2014.864276DOI Listing
February 2014

Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.

Future Oncol 2013 Aug;9(8):1073-82

Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.13.130DOI Listing
August 2013

Characteristics and outcome of acute myeloid leukemia in patients with a prior history of autoimmune disease.

Leuk Lymphoma 2013 Jun 19;54(6):1235-41. Epub 2013 Feb 19.

Abramson Cancer Center, Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2012.736982DOI Listing
June 2013

Isolated myeloid sarcoma of the genitourinary system.

Clin Adv Hematol Oncol 2013 Jun;11(6):393-4

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
June 2013

Beyond morphology: minimal residual disease detection in acute myeloid leukemia.

Curr Opin Hematol 2012 Mar;19(2):82-8

Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOH.0b013e3283501325DOI Listing
March 2012

Treatment advances in posttransplant lymphoproliferative disease.

Curr Opin Hematol 2010 Jul;17(4):368-74

Department of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania, Pennsylvania, Philadelphia 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOH.0b013e328339018cDOI Listing
July 2010

Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene.

Med Oncol 2008 8;25(3):299-302. Epub 2008 Jan 8.

Department of Internal Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-007-9035-xDOI Listing
December 2008

Applications and implications of advances in human genetics: perspectives from a group of Black Americans.

Community Genet 2007 ;10(2):82-92

Department of Behavioral Sciences, University of Michigan-Dearborn, Dearborn, Mich., USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000099085DOI Listing
April 2007